|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Diabetic Gastroparesis | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Gastroparesis | |||||
| 3 | More general conditions related to this trial | ||||
| Digestive System Diseases | |||||
| Gastrointestinal Diseases | |||||
| Neurologic Manifestations | |||||
| Paralysis | |||||
| Signs and Symptoms | |||||
| Stomach Diseases | |||||
| 4 | Interventions listed in this trial | ||||
| Reglan ODT | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Metoclopramide | |||||
| 6 | More general drug interventions related to this trial | ||||
| Antiemetics | |||||
| Autonomic Agents | |||||
| Central Nervous System Agents | |||||
| Dopamine Agents | |||||
| Dopamine Antagonists | |||||
| Gastrointestinal Agents | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Neurotransmitter Agents | |||||
| Peripheral Nervous System Agents | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Therapeutic Uses | |||||
| 7 | Sponsors listed in this trial | ||||
| UCB | |||||